Science, vision, and skin health in one brand

Epicutis has its origins in more than four decades of scientific research by Dr. Jeffry Stock at Princeton University. His work on inflammatory processes at the cellular level led to the development of Isoprenyl Cysteines (IPCs), which formed the basis for Signum Biosciences and later Epicutis as a professional skincare brand.

Instead of merely addressing symptoms, Epicutis focuses on supporting underlying skin processes, with an emphasis on restoration, balance, and a healthy skin barrier. This vision was translated into a clinically applicable brand by Maxwell Stock and Lisa Johnson, in collaboration with formulator Masanori Tamura.

The result is a professional skincare line with minimalist, targeted formulations that soothe the skin and support its recovery. Epicutis is developed for integration into aesthetic treatments and positions itself as a bridge between pharmaceutical science and high-end skin improvement, with an emphasis on safety, transparency, and non-toxic formulation.

Epicutis applies the rigor of drug discovery and biotechnological research to professional skincare, using the same principles of precision, safety, and efficacy as in pharmaceutical development. This approach ensures that formulations are not only aesthetically appealing but also scientifically sound and consistently applicable in clinical practice.

The patented actives are designed not only to work on the surface but also to support relevant biological processes in the skin, particularly concerning inflammatory responses, repair mechanisms, and barrier function. As a result, Epicutis focuses not merely on visible improvement, but on creating a stable and healthy skin condition as the basis for long-lasting results.